Search Results - "Guerreiro, Gabriel Tayguara Silveira"
-
1
Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Published in Hepatology international (01-04-2021)“…Background/purpose Cardiovascular disease (CVD) is the leading cause of death among individuals with non-alcoholic fatty liver disease (NAFLD). Recently, NAFLD…”
Get full text
Journal Article -
2
Nicotinamide riboside and dietary restriction effects on gut microbiota and liver inflammatory and morphologic markers in cafeteria diet–induced obesity in rats
Published in Nutrition (Burbank, Los Angeles County, Calif.) (01-06-2023)“…•The cafeteria diet rapidly and effectively causes metabolic dysfunction–associated fatty liver disease.•The cafeteria diet does not modulate genes involved in…”
Get full text
Journal Article -
3
Hepatoprotective Effect of Probiotic Lactobacillus rhamnosus GG Through the Modulation of Gut Permeability and Inflammasomes in a Model of Alcoholic Liver Disease in Zebrafish
Published in Journal of the American College of Nutrition (17-02-2020)“…Objective: Alcoholic liver disease (ALD) is among the leading causes of death from liver disease. Among the factors involved in its pathogenesis are…”
Get full text
Journal Article -
4
Changes in the gut microbiota of rats after exposure to the fungicide Mancozeb
Published in Toxicology and applied pharmacology (01-05-2023)“…Mancozeb is a fungicide commonly used in pest control programs, especially to protect vineyards. Its toxicity has already been evidenced in several studies…”
Get full text
Journal Article -
5
Firmicutes/Bacteroidetes and Firmicutes/Proteobacteria ratios are associated with worse prognosis in a cohort of Latin American patients with cirrhosis
Published in Clinics (São Paulo, Brazil) (01-01-2024)“…•Gut Microbiota (GM) has an important role in liver diseases progression.•Notable differences in GM and diversity exist between healthy individuals and…”
Get full text
Journal Article -
6
Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease
Published in World journal of hepatology (27-01-2024)“…Prevalence of hepatocellular carcinoma (HCC) is increasing, especially in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). To…”
Get full text
Journal Article -
7
Rifaximin prophylaxis in MASLD‑hepatocellular carcinoma: Lessons from a negative animal model
Published in Biomedical reports (24-10-2024)“…The incidence of hepatocellular carcinoma (HCC) has been rising, particularly among individuals diagnosed with metabolic dysfunction-associated steatotic liver…”
Get full text
Journal Article -
8
Potential Beneficial Effect of Rifaximin in the Prevention of Hepatocellular Carcinoma through the Modulation of the Microbiota in an Experimental Model of Non-alcoholic Fatty Liver Disease
Published in Acta gastroenterologica latinoamericana (30-09-2023)“…Aim. To evaluate the effects of rifaximin through microbiota modulation in a model of hepatocellular carcinoma secondary to non-alcoholic fatty liver disease…”
Get full text
Journal Article